nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCB1—kidney cancer	0.166	1	CbGaD
Canagliflozin—UGT1A9—Sorafenib—kidney cancer	0.0556	0.111	CbGbCtD
Canagliflozin—ORM1—Erlotinib—kidney cancer	0.0504	0.101	CbGbCtD
Canagliflozin—ABCC2—Paclitaxel—kidney cancer	0.0311	0.0622	CbGbCtD
Canagliflozin—ABCB1—Temsirolimus—kidney cancer	0.0296	0.0591	CbGbCtD
Canagliflozin—ABCC2—Sorafenib—kidney cancer	0.0277	0.0553	CbGbCtD
Canagliflozin—ABCC2—Vinblastine—kidney cancer	0.0273	0.0546	CbGbCtD
Canagliflozin—ABCC2—Vincristine—kidney cancer	0.0269	0.0537	CbGbCtD
Canagliflozin—CYP3A4—Everolimus—kidney cancer	0.0262	0.0524	CbGbCtD
Canagliflozin—ABCC2—Sunitinib—kidney cancer	0.0224	0.0448	CbGbCtD
Canagliflozin—SLC5A2—nephron—kidney cancer	0.0215	0.26	CbGeAlD
Canagliflozin—ALB—Erlotinib—kidney cancer	0.0212	0.0424	CbGbCtD
Canagliflozin—CYP3A4—Temsirolimus—kidney cancer	0.0177	0.0354	CbGbCtD
Canagliflozin—SLC5A2—urine—kidney cancer	0.0172	0.209	CbGeAlD
Canagliflozin—ABCC2—Doxorubicin—kidney cancer	0.0168	0.0335	CbGbCtD
Canagliflozin—ABCB1—Pazopanib—kidney cancer	0.0155	0.0311	CbGbCtD
Canagliflozin—ABCB1—Dactinomycin—kidney cancer	0.0142	0.0284	CbGbCtD
Canagliflozin—ABCB1—Gemcitabine—kidney cancer	0.0112	0.0225	CbGbCtD
Canagliflozin—ABCB1—Erlotinib—kidney cancer	0.0111	0.0222	CbGbCtD
Canagliflozin—ABCB1—Paclitaxel—kidney cancer	0.0102	0.0203	CbGbCtD
Canagliflozin—CYP3A4—Pazopanib—kidney cancer	0.00931	0.0186	CbGbCtD
Canagliflozin—ABCB1—Sorafenib—kidney cancer	0.00902	0.018	CbGbCtD
Canagliflozin—ABCB1—Vinblastine—kidney cancer	0.0089	0.0178	CbGbCtD
Canagliflozin—ABCB1—Vincristine—kidney cancer	0.00875	0.0175	CbGbCtD
Canagliflozin—ABCB1—Sunitinib—kidney cancer	0.00731	0.0146	CbGbCtD
Canagliflozin—CYP3A4—Erlotinib—kidney cancer	0.00664	0.0133	CbGbCtD
Canagliflozin—CYP3A4—Paclitaxel—kidney cancer	0.00608	0.0122	CbGbCtD
Canagliflozin—ABCB1—Doxorubicin—kidney cancer	0.00547	0.0109	CbGbCtD
Canagliflozin—CYP3A4—Sorafenib—kidney cancer	0.0054	0.0108	CbGbCtD
Canagliflozin—CYP3A4—Vinblastine—kidney cancer	0.00534	0.0107	CbGbCtD
Canagliflozin—CYP3A4—Vincristine—kidney cancer	0.00525	0.0105	CbGbCtD
Canagliflozin—SLC5A2—nephron tubule—kidney cancer	0.00463	0.0562	CbGeAlD
Canagliflozin—CYP3A4—Sunitinib—kidney cancer	0.00438	0.00875	CbGbCtD
Canagliflozin—SLC5A2—renal system—kidney cancer	0.00421	0.0511	CbGeAlD
Canagliflozin—SLC5A2—kidney—kidney cancer	0.00407	0.0494	CbGeAlD
Canagliflozin—SLC5A2—cortex of kidney—kidney cancer	0.00397	0.0481	CbGeAlD
Canagliflozin—SLC5A1—nephron tubule—kidney cancer	0.00351	0.0426	CbGeAlD
Canagliflozin—CYP3A4—Doxorubicin—kidney cancer	0.00328	0.00655	CbGbCtD
Canagliflozin—SLC5A1—renal system—kidney cancer	0.00319	0.0387	CbGeAlD
Canagliflozin—SLC5A1—kidney—kidney cancer	0.00309	0.0374	CbGeAlD
Canagliflozin—SLC5A1—cardiac atrium—kidney cancer	0.00286	0.0347	CbGeAlD
Canagliflozin—UGT2B4—cardiac atrium—kidney cancer	0.00263	0.0319	CbGeAlD
Canagliflozin—UGT1A9—renal system—kidney cancer	0.00201	0.0244	CbGeAlD
Canagliflozin—UGT1A9—kidney—kidney cancer	0.00194	0.0235	CbGeAlD
Canagliflozin—Dapagliflozin—CYP1A1—kidney cancer	0.00188	0.653	CrCbGaD
Canagliflozin—CYP3A4—urine—kidney cancer	0.0018	0.0219	CbGeAlD
Canagliflozin—Dapagliflozin—ABCB1—kidney cancer	0.001	0.347	CrCbGaD
Canagliflozin—ABCC2—nephron tubule—kidney cancer	0.000956	0.0116	CbGeAlD
Canagliflozin—ABCC2—renal system—kidney cancer	0.000869	0.0105	CbGeAlD
Canagliflozin—ABCC2—kidney—kidney cancer	0.00084	0.0102	CbGeAlD
Canagliflozin—ABCC2—cortex of kidney—kidney cancer	0.000818	0.00992	CbGeAlD
Canagliflozin—CYP3A4—renal system—kidney cancer	0.000441	0.00535	CbGeAlD
Canagliflozin—CYP3A4—kidney—kidney cancer	0.000427	0.00517	CbGeAlD
Canagliflozin—ABCB1—nephron tubule—kidney cancer	0.000344	0.00417	CbGeAlD
Canagliflozin—ABCB1—renal system—kidney cancer	0.000312	0.00379	CbGeAlD
Canagliflozin—ABCB1—kidney—kidney cancer	0.000302	0.00366	CbGeAlD
Canagliflozin—ABCB1—cortex of kidney—kidney cancer	0.000294	0.00357	CbGeAlD
Canagliflozin—ABCB1—gonad—kidney cancer	0.00028	0.0034	CbGeAlD
Canagliflozin—Shock—Everolimus—kidney cancer	0.000234	0.00154	CcSEcCtD
Canagliflozin—Urinary tract disorder—Vincristine—kidney cancer	0.000233	0.00154	CcSEcCtD
Canagliflozin—Nervous system disorder—Everolimus—kidney cancer	0.000233	0.00153	CcSEcCtD
Canagliflozin—Urethral disorder—Vincristine—kidney cancer	0.000232	0.00153	CcSEcCtD
Canagliflozin—Angioedema—Sorafenib—kidney cancer	0.000231	0.00152	CcSEcCtD
Canagliflozin—Skin disorder—Everolimus—kidney cancer	0.000231	0.00152	CcSEcCtD
Canagliflozin—Erythema—Dactinomycin—kidney cancer	0.00023	0.00152	CcSEcCtD
Canagliflozin—Pancreatitis—Paclitaxel—kidney cancer	0.00023	0.00151	CcSEcCtD
Canagliflozin—Asthenia—Temsirolimus—kidney cancer	0.000229	0.00151	CcSEcCtD
Canagliflozin—Infection—Erlotinib—kidney cancer	0.000228	0.0015	CcSEcCtD
Canagliflozin—Syncope—Sorafenib—kidney cancer	0.000227	0.00149	CcSEcCtD
Canagliflozin—Pruritus—Temsirolimus—kidney cancer	0.000226	0.00149	CcSEcCtD
Canagliflozin—Shock—Erlotinib—kidney cancer	0.000226	0.00149	CcSEcCtD
Canagliflozin—Nervous system disorder—Erlotinib—kidney cancer	0.000225	0.00148	CcSEcCtD
Canagliflozin—Skin disorder—Erlotinib—kidney cancer	0.000223	0.00147	CcSEcCtD
Canagliflozin—Angioedema—Sunitinib—kidney cancer	0.000222	0.00146	CcSEcCtD
Canagliflozin—Loss of consciousness—Sorafenib—kidney cancer	0.000222	0.00146	CcSEcCtD
Canagliflozin—Hypotension—Everolimus—kidney cancer	0.000222	0.00146	CcSEcCtD
Canagliflozin—Urinary tract disorder—Gemcitabine—kidney cancer	0.000221	0.00146	CcSEcCtD
Canagliflozin—Urethral disorder—Gemcitabine—kidney cancer	0.00022	0.00145	CcSEcCtD
Canagliflozin—Pollakiuria—Paclitaxel—kidney cancer	0.000217	0.00143	CcSEcCtD
Canagliflozin—Asthenia—Pazopanib—kidney cancer	0.000216	0.00142	CcSEcCtD
Canagliflozin—Angiopathy—Vincristine—kidney cancer	0.000214	0.00141	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Paclitaxel—kidney cancer	0.000214	0.00141	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000214	0.00141	CcSEcCtD
Canagliflozin—Nocturia—Doxorubicin—kidney cancer	0.000213	0.0014	CcSEcCtD
Canagliflozin—Pruritus—Pazopanib—kidney cancer	0.000213	0.0014	CcSEcCtD
Canagliflozin—Dizziness—Temsirolimus—kidney cancer	0.000211	0.00139	CcSEcCtD
Canagliflozin—Convulsion—Sunitinib—kidney cancer	0.000211	0.00139	CcSEcCtD
Canagliflozin—Dry mouth—Sorafenib—kidney cancer	0.00021	0.00139	CcSEcCtD
Canagliflozin—Blood creatinine increased—Capecitabine—kidney cancer	0.000209	0.00137	CcSEcCtD
Canagliflozin—Dehydration—Capecitabine—kidney cancer	0.000207	0.00136	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000206	0.00135	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Everolimus—kidney cancer	0.000205	0.00135	CcSEcCtD
Canagliflozin—Infection—Sorafenib—kidney cancer	0.000205	0.00135	CcSEcCtD
Canagliflozin—Fatigue—Everolimus—kidney cancer	0.000205	0.00135	CcSEcCtD
Canagliflozin—Constipation—Vinblastine—kidney cancer	0.000204	0.00134	CcSEcCtD
Canagliflozin—Angiopathy—Gemcitabine—kidney cancer	0.000203	0.00134	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Capecitabine—kidney cancer	0.000203	0.00134	CcSEcCtD
Canagliflozin—Urinary tract infection—Paclitaxel—kidney cancer	0.000203	0.00134	CcSEcCtD
Canagliflozin—Constipation—Everolimus—kidney cancer	0.000203	0.00134	CcSEcCtD
Canagliflozin—Shock—Sorafenib—kidney cancer	0.000203	0.00134	CcSEcCtD
Canagliflozin—Dry mouth—Sunitinib—kidney cancer	0.000203	0.00133	CcSEcCtD
Canagliflozin—Nervous system disorder—Sorafenib—kidney cancer	0.000202	0.00133	CcSEcCtD
Canagliflozin—Rash—Temsirolimus—kidney cancer	0.000201	0.00133	CcSEcCtD
Canagliflozin—Dermatitis—Temsirolimus—kidney cancer	0.000201	0.00133	CcSEcCtD
Canagliflozin—Breast disorder—Capecitabine—kidney cancer	0.000201	0.00133	CcSEcCtD
Canagliflozin—Skin disorder—Sorafenib—kidney cancer	0.0002	0.00132	CcSEcCtD
Canagliflozin—Dizziness—Pazopanib—kidney cancer	0.000199	0.00131	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000198	0.0013	CcSEcCtD
Canagliflozin—Fatigue—Erlotinib—kidney cancer	0.000198	0.0013	CcSEcCtD
Canagliflozin—Infection—Sunitinib—kidney cancer	0.000197	0.0013	CcSEcCtD
Canagliflozin—Constipation—Erlotinib—kidney cancer	0.000196	0.00129	CcSEcCtD
Canagliflozin—Shock—Sunitinib—kidney cancer	0.000195	0.00129	CcSEcCtD
Canagliflozin—Erythema—Gemcitabine—kidney cancer	0.000195	0.00129	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vinblastine—kidney cancer	0.000195	0.00128	CcSEcCtD
Canagliflozin—Nervous system disorder—Sunitinib—kidney cancer	0.000195	0.00128	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Everolimus—kidney cancer	0.000194	0.00128	CcSEcCtD
Canagliflozin—Hyperkalaemia—Doxorubicin—kidney cancer	0.000194	0.00128	CcSEcCtD
Canagliflozin—Cystitis noninfective—Doxorubicin—kidney cancer	0.000193	0.00127	CcSEcCtD
Canagliflozin—Skin disorder—Sunitinib—kidney cancer	0.000193	0.00127	CcSEcCtD
Canagliflozin—Cystitis—Doxorubicin—kidney cancer	0.000191	0.00126	CcSEcCtD
Canagliflozin—Rash—Pazopanib—kidney cancer	0.00019	0.00125	CcSEcCtD
Canagliflozin—Nausea—Temsirolimus—kidney cancer	0.00019	0.00125	CcSEcCtD
Canagliflozin—Dermatitis—Pazopanib—kidney cancer	0.00019	0.00125	CcSEcCtD
Canagliflozin—Abdominal pain—Vinblastine—kidney cancer	0.000189	0.00124	CcSEcCtD
Canagliflozin—Abdominal pain—Everolimus—kidney cancer	0.000188	0.00124	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Erlotinib—kidney cancer	0.000188	0.00123	CcSEcCtD
Canagliflozin—Infection—Dactinomycin—kidney cancer	0.000187	0.00123	CcSEcCtD
Canagliflozin—Vaginal infection—Doxorubicin—kidney cancer	0.000187	0.00123	CcSEcCtD
Canagliflozin—Blood urea increased—Doxorubicin—kidney cancer	0.000187	0.00123	CcSEcCtD
Canagliflozin—Urinary tract disorder—Paclitaxel—kidney cancer	0.000185	0.00122	CcSEcCtD
Canagliflozin—Urethral disorder—Paclitaxel—kidney cancer	0.000184	0.00121	CcSEcCtD
Canagliflozin—Abdominal pain—Erlotinib—kidney cancer	0.000181	0.00119	CcSEcCtD
Canagliflozin—Rash maculo-papular—Doxorubicin—kidney cancer	0.00018	0.00118	CcSEcCtD
Canagliflozin—Nausea—Pazopanib—kidney cancer	0.000179	0.00118	CcSEcCtD
Canagliflozin—Bladder pain—Doxorubicin—kidney cancer	0.000179	0.00118	CcSEcCtD
Canagliflozin—Convulsion—Vincristine—kidney cancer	0.000178	0.00117	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000178	0.00117	CcSEcCtD
Canagliflozin—Fatigue—Sorafenib—kidney cancer	0.000178	0.00117	CcSEcCtD
Canagliflozin—Constipation—Sorafenib—kidney cancer	0.000176	0.00116	CcSEcCtD
Canagliflozin—Hypersensitivity—Vinblastine—kidney cancer	0.000176	0.00116	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Capecitabine—kidney cancer	0.000176	0.00116	CcSEcCtD
Canagliflozin—Hypersensitivity—Everolimus—kidney cancer	0.000175	0.00115	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000171	0.00113	CcSEcCtD
Canagliflozin—Asthenia—Vinblastine—kidney cancer	0.000171	0.00113	CcSEcCtD
Canagliflozin—Fatigue—Sunitinib—kidney cancer	0.000171	0.00113	CcSEcCtD
Canagliflozin—Asthenia—Everolimus—kidney cancer	0.000171	0.00112	CcSEcCtD
Canagliflozin—Angiopathy—Paclitaxel—kidney cancer	0.00017	0.00112	CcSEcCtD
Canagliflozin—Constipation—Sunitinib—kidney cancer	0.00017	0.00112	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Sorafenib—kidney cancer	0.000169	0.00111	CcSEcCtD
Canagliflozin—Pruritus—Everolimus—kidney cancer	0.000168	0.00111	CcSEcCtD
Canagliflozin—Infection—Vincristine—kidney cancer	0.000167	0.0011	CcSEcCtD
Canagliflozin—Urinary tract infection—Capecitabine—kidney cancer	0.000167	0.0011	CcSEcCtD
Canagliflozin—Diabetes mellitus—Doxorubicin—kidney cancer	0.000165	0.00109	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000165	0.00109	CcSEcCtD
Canagliflozin—Nervous system disorder—Vincristine—kidney cancer	0.000165	0.00108	CcSEcCtD
Canagliflozin—Asthenia—Erlotinib—kidney cancer	0.000165	0.00108	CcSEcCtD
Canagliflozin—Urticaria—Sorafenib—kidney cancer	0.000164	0.00108	CcSEcCtD
Canagliflozin—Photosensitivity—Doxorubicin—kidney cancer	0.000163	0.00108	CcSEcCtD
Canagliflozin—Erythema—Paclitaxel—kidney cancer	0.000163	0.00108	CcSEcCtD
Canagliflozin—Malnutrition—Paclitaxel—kidney cancer	0.000163	0.00108	CcSEcCtD
Canagliflozin—Abdominal pain—Sorafenib—kidney cancer	0.000163	0.00107	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Sunitinib—kidney cancer	0.000162	0.00107	CcSEcCtD
Canagliflozin—Pruritus—Erlotinib—kidney cancer	0.000162	0.00107	CcSEcCtD
Canagliflozin—Fatigue—Dactinomycin—kidney cancer	0.000162	0.00107	CcSEcCtD
Canagliflozin—Infection—Gemcitabine—kidney cancer	0.000158	0.00104	CcSEcCtD
Canagliflozin—Dizziness—Vinblastine—kidney cancer	0.000158	0.00104	CcSEcCtD
Canagliflozin—Dizziness—Everolimus—kidney cancer	0.000157	0.00103	CcSEcCtD
Canagliflozin—Abdominal pain—Sunitinib—kidney cancer	0.000157	0.00103	CcSEcCtD
Canagliflozin—Hypotension—Vincristine—kidney cancer	0.000157	0.00103	CcSEcCtD
Canagliflozin—Nervous system disorder—Gemcitabine—kidney cancer	0.000156	0.00103	CcSEcCtD
Canagliflozin—Renal failure acute—Doxorubicin—kidney cancer	0.000155	0.00102	CcSEcCtD
Canagliflozin—Skin disorder—Gemcitabine—kidney cancer	0.000155	0.00102	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000154	0.00101	CcSEcCtD
Canagliflozin—Urinary tract disorder—Capecitabine—kidney cancer	0.000152	0.001	CcSEcCtD
Canagliflozin—Hypersensitivity—Sorafenib—kidney cancer	0.000152	0.001	CcSEcCtD
Canagliflozin—Dizziness—Erlotinib—kidney cancer	0.000152	0.000999	CcSEcCtD
Canagliflozin—Urethral disorder—Capecitabine—kidney cancer	0.000151	0.000994	CcSEcCtD
Canagliflozin—Rash—Everolimus—kidney cancer	0.00015	0.000987	CcSEcCtD
Canagliflozin—Dermatitis—Everolimus—kidney cancer	0.00015	0.000986	CcSEcCtD
Canagliflozin—Angioedema—Paclitaxel—kidney cancer	0.000149	0.000983	CcSEcCtD
Canagliflozin—Hypotension—Gemcitabine—kidney cancer	0.000149	0.00098	CcSEcCtD
Canagliflozin—Abdominal pain—Dactinomycin—kidney cancer	0.000149	0.000978	CcSEcCtD
Canagliflozin—Asthenia—Sorafenib—kidney cancer	0.000148	0.000975	CcSEcCtD
Canagliflozin—Hypoglycaemia—Doxorubicin—kidney cancer	0.000147	0.000969	CcSEcCtD
Canagliflozin—Syncope—Paclitaxel—kidney cancer	0.000147	0.000965	CcSEcCtD
Canagliflozin—Hypersensitivity—Sunitinib—kidney cancer	0.000146	0.000963	CcSEcCtD
Canagliflozin—Pruritus—Sorafenib—kidney cancer	0.000146	0.000961	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000145	0.000955	CcSEcCtD
Canagliflozin—Fatigue—Vincristine—kidney cancer	0.000145	0.000953	CcSEcCtD
Canagliflozin—Rash—Erlotinib—kidney cancer	0.000145	0.000952	CcSEcCtD
Canagliflozin—Dermatitis—Erlotinib—kidney cancer	0.000144	0.000951	CcSEcCtD
Canagliflozin—Loss of consciousness—Paclitaxel—kidney cancer	0.000144	0.000946	CcSEcCtD
Canagliflozin—Constipation—Vincristine—kidney cancer	0.000144	0.000946	CcSEcCtD
Canagliflozin—Asthenia—Sunitinib—kidney cancer	0.000142	0.000938	CcSEcCtD
Canagliflozin—Nausea—Vinblastine—kidney cancer	0.000142	0.000933	CcSEcCtD
Canagliflozin—Convulsion—Paclitaxel—kidney cancer	0.000142	0.000932	CcSEcCtD
Canagliflozin—Nausea—Everolimus—kidney cancer	0.000141	0.00093	CcSEcCtD
Canagliflozin—Pruritus—Sunitinib—kidney cancer	0.00014	0.000925	CcSEcCtD
Canagliflozin—Angiopathy—Capecitabine—kidney cancer	0.00014	0.00092	CcSEcCtD
Canagliflozin—Hypersensitivity—Dactinomycin—kidney cancer	0.000138	0.000912	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000138	0.00091	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000138	0.000906	CcSEcCtD
Canagliflozin—Fatigue—Gemcitabine—kidney cancer	0.000137	0.000904	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Vincristine—kidney cancer	0.000137	0.000904	CcSEcCtD
Canagliflozin—Dizziness—Sorafenib—kidney cancer	0.000136	0.000898	CcSEcCtD
Canagliflozin—Constipation—Gemcitabine—kidney cancer	0.000136	0.000897	CcSEcCtD
Canagliflozin—Nausea—Erlotinib—kidney cancer	0.000136	0.000897	CcSEcCtD
Canagliflozin—Dry mouth—Paclitaxel—kidney cancer	0.000136	0.000896	CcSEcCtD
Canagliflozin—Asthenia—Dactinomycin—kidney cancer	0.000135	0.000888	CcSEcCtD
Canagliflozin—Blood creatinine increased—Doxorubicin—kidney cancer	0.000134	0.000886	CcSEcCtD
Canagliflozin—Malnutrition—Capecitabine—kidney cancer	0.000134	0.000883	CcSEcCtD
Canagliflozin—Erythema—Capecitabine—kidney cancer	0.000134	0.000883	CcSEcCtD
Canagliflozin—Dehydration—Doxorubicin—kidney cancer	0.000133	0.000879	CcSEcCtD
Canagliflozin—Abdominal pain—Vincristine—kidney cancer	0.000133	0.000874	CcSEcCtD
Canagliflozin—Infection—Paclitaxel—kidney cancer	0.000132	0.000872	CcSEcCtD
Canagliflozin—Dizziness—Sunitinib—kidney cancer	0.000131	0.000864	CcSEcCtD
Canagliflozin—Shock—Paclitaxel—kidney cancer	0.000131	0.000864	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000131	0.000863	CcSEcCtD
Canagliflozin—Nervous system disorder—Paclitaxel—kidney cancer	0.000131	0.000861	CcSEcCtD
Canagliflozin—Rash—Sorafenib—kidney cancer	0.00013	0.000857	CcSEcCtD
Canagliflozin—Dermatitis—Sorafenib—kidney cancer	0.00013	0.000856	CcSEcCtD
Canagliflozin—Breast disorder—Doxorubicin—kidney cancer	0.00013	0.000854	CcSEcCtD
Canagliflozin—Skin disorder—Paclitaxel—kidney cancer	0.00013	0.000853	CcSEcCtD
Canagliflozin—Rash—Sunitinib—kidney cancer	0.000125	0.000824	CcSEcCtD
Canagliflozin—Dermatitis—Sunitinib—kidney cancer	0.000125	0.000824	CcSEcCtD
Canagliflozin—Hypotension—Paclitaxel—kidney cancer	0.000125	0.000821	CcSEcCtD
Canagliflozin—Hypersensitivity—Vincristine—kidney cancer	0.000124	0.000815	CcSEcCtD
Canagliflozin—Nausea—Sorafenib—kidney cancer	0.000123	0.000807	CcSEcCtD
Canagliflozin—Pancreatitis—Doxorubicin—kidney cancer	0.000122	0.000801	CcSEcCtD
Canagliflozin—Asthenia—Vincristine—kidney cancer	0.00012	0.000793	CcSEcCtD
Canagliflozin—Syncope—Capecitabine—kidney cancer	0.00012	0.000792	CcSEcCtD
Canagliflozin—Rash—Dactinomycin—kidney cancer	0.000119	0.00078	CcSEcCtD
Canagliflozin—Nausea—Sunitinib—kidney cancer	0.000118	0.000777	CcSEcCtD
Canagliflozin—Loss of consciousness—Capecitabine—kidney cancer	0.000118	0.000776	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000115	0.000758	CcSEcCtD
Canagliflozin—Fatigue—Paclitaxel—kidney cancer	0.000115	0.000757	CcSEcCtD
Canagliflozin—Pollakiuria—Doxorubicin—kidney cancer	0.000115	0.000755	CcSEcCtD
Canagliflozin—Asthenia—Gemcitabine—kidney cancer	0.000114	0.000753	CcSEcCtD
Canagliflozin—Constipation—Paclitaxel—kidney cancer	0.000114	0.000751	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000113	0.000747	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000113	0.000746	CcSEcCtD
Canagliflozin—Pruritus—Gemcitabine—kidney cancer	0.000113	0.000742	CcSEcCtD
Canagliflozin—Dry mouth—Capecitabine—kidney cancer	0.000112	0.000735	CcSEcCtD
Canagliflozin—Nausea—Dactinomycin—kidney cancer	0.000112	0.000735	CcSEcCtD
Canagliflozin—Dizziness—Vincristine—kidney cancer	0.000111	0.000731	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000109	0.000718	CcSEcCtD
Canagliflozin—Infection—Capecitabine—kidney cancer	0.000109	0.000716	CcSEcCtD
Canagliflozin—Shock—Capecitabine—kidney cancer	0.000108	0.000709	CcSEcCtD
Canagliflozin—Urinary tract infection—Doxorubicin—kidney cancer	0.000108	0.000708	CcSEcCtD
Canagliflozin—Nervous system disorder—Capecitabine—kidney cancer	0.000107	0.000707	CcSEcCtD
Canagliflozin—Skin disorder—Capecitabine—kidney cancer	0.000106	0.0007	CcSEcCtD
Canagliflozin—Urticaria—Paclitaxel—kidney cancer	0.000106	0.000698	CcSEcCtD
Canagliflozin—Rash—Vincristine—kidney cancer	0.000106	0.000697	CcSEcCtD
Canagliflozin—Dermatitis—Vincristine—kidney cancer	0.000106	0.000697	CcSEcCtD
Canagliflozin—Abdominal pain—Paclitaxel—kidney cancer	0.000105	0.000694	CcSEcCtD
Canagliflozin—Hypotension—Capecitabine—kidney cancer	0.000102	0.000673	CcSEcCtD
Canagliflozin—Rash—Gemcitabine—kidney cancer	0.0001	0.000661	CcSEcCtD
Canagliflozin—Dermatitis—Gemcitabine—kidney cancer	0.0001	0.000661	CcSEcCtD
Canagliflozin—Nausea—Vincristine—kidney cancer	9.97e-05	0.000657	CcSEcCtD
Canagliflozin—Hypersensitivity—Paclitaxel—kidney cancer	9.83e-05	0.000647	CcSEcCtD
Canagliflozin—Urinary tract disorder—Doxorubicin—kidney cancer	9.81e-05	0.000646	CcSEcCtD
Canagliflozin—Urethral disorder—Doxorubicin—kidney cancer	9.73e-05	0.000641	CcSEcCtD
Canagliflozin—Asthenia—Paclitaxel—kidney cancer	9.57e-05	0.00063	CcSEcCtD
Canagliflozin—Nausea—Gemcitabine—kidney cancer	9.46e-05	0.000623	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Capecitabine—kidney cancer	9.45e-05	0.000622	CcSEcCtD
Canagliflozin—Fatigue—Capecitabine—kidney cancer	9.44e-05	0.000621	CcSEcCtD
Canagliflozin—Pruritus—Paclitaxel—kidney cancer	9.44e-05	0.000621	CcSEcCtD
Canagliflozin—Constipation—Capecitabine—kidney cancer	9.36e-05	0.000616	CcSEcCtD
Canagliflozin—Angiopathy—Doxorubicin—kidney cancer	9.01e-05	0.000593	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Capecitabine—kidney cancer	8.95e-05	0.000589	CcSEcCtD
Canagliflozin—Dizziness—Paclitaxel—kidney cancer	8.82e-05	0.000581	CcSEcCtD
Canagliflozin—Urticaria—Capecitabine—kidney cancer	8.69e-05	0.000573	CcSEcCtD
Canagliflozin—Abdominal pain—Capecitabine—kidney cancer	8.65e-05	0.00057	CcSEcCtD
Canagliflozin—Malnutrition—Doxorubicin—kidney cancer	8.64e-05	0.000569	CcSEcCtD
Canagliflozin—Erythema—Doxorubicin—kidney cancer	8.64e-05	0.000569	CcSEcCtD
Canagliflozin—Rash—Paclitaxel—kidney cancer	8.41e-05	0.000554	CcSEcCtD
Canagliflozin—Dermatitis—Paclitaxel—kidney cancer	8.4e-05	0.000553	CcSEcCtD
Canagliflozin—Hypersensitivity—Capecitabine—kidney cancer	8.06e-05	0.000531	CcSEcCtD
Canagliflozin—Nausea—Paclitaxel—kidney cancer	7.92e-05	0.000522	CcSEcCtD
Canagliflozin—Asthenia—Capecitabine—kidney cancer	7.85e-05	0.000517	CcSEcCtD
Canagliflozin—Syncope—Doxorubicin—kidney cancer	7.75e-05	0.00051	CcSEcCtD
Canagliflozin—Pruritus—Capecitabine—kidney cancer	7.74e-05	0.00051	CcSEcCtD
Canagliflozin—Loss of consciousness—Doxorubicin—kidney cancer	7.6e-05	0.0005	CcSEcCtD
Canagliflozin—Convulsion—Doxorubicin—kidney cancer	7.49e-05	0.000493	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.31e-05	0.000481	CcSEcCtD
Canagliflozin—Dizziness—Capecitabine—kidney cancer	7.24e-05	0.000477	CcSEcCtD
Canagliflozin—Dry mouth—Doxorubicin—kidney cancer	7.2e-05	0.000474	CcSEcCtD
Canagliflozin—Infection—Doxorubicin—kidney cancer	7.01e-05	0.000462	CcSEcCtD
Canagliflozin—Shock—Doxorubicin—kidney cancer	6.94e-05	0.000457	CcSEcCtD
Canagliflozin—Nervous system disorder—Doxorubicin—kidney cancer	6.92e-05	0.000456	CcSEcCtD
Canagliflozin—Rash—Capecitabine—kidney cancer	6.9e-05	0.000454	CcSEcCtD
Canagliflozin—Dermatitis—Capecitabine—kidney cancer	6.89e-05	0.000454	CcSEcCtD
Canagliflozin—Skin disorder—Doxorubicin—kidney cancer	6.85e-05	0.000451	CcSEcCtD
Canagliflozin—Hypotension—Doxorubicin—kidney cancer	6.59e-05	0.000434	CcSEcCtD
Canagliflozin—Nausea—Capecitabine—kidney cancer	6.5e-05	0.000428	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Doxorubicin—kidney cancer	6.09e-05	0.000401	CcSEcCtD
Canagliflozin—Fatigue—Doxorubicin—kidney cancer	6.08e-05	0.000401	CcSEcCtD
Canagliflozin—Constipation—Doxorubicin—kidney cancer	6.03e-05	0.000397	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Doxorubicin—kidney cancer	5.77e-05	0.00038	CcSEcCtD
Canagliflozin—Urticaria—Doxorubicin—kidney cancer	5.6e-05	0.000369	CcSEcCtD
Canagliflozin—Abdominal pain—Doxorubicin—kidney cancer	5.58e-05	0.000367	CcSEcCtD
Canagliflozin—Hypersensitivity—Doxorubicin—kidney cancer	5.2e-05	0.000342	CcSEcCtD
Canagliflozin—Asthenia—Doxorubicin—kidney cancer	5.06e-05	0.000333	CcSEcCtD
Canagliflozin—Pruritus—Doxorubicin—kidney cancer	4.99e-05	0.000329	CcSEcCtD
Canagliflozin—Dizziness—Doxorubicin—kidney cancer	4.67e-05	0.000307	CcSEcCtD
Canagliflozin—Rash—Doxorubicin—kidney cancer	4.45e-05	0.000293	CcSEcCtD
Canagliflozin—Dermatitis—Doxorubicin—kidney cancer	4.44e-05	0.000293	CcSEcCtD
Canagliflozin—Nausea—Doxorubicin—kidney cancer	4.19e-05	0.000276	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—ABCB1—kidney cancer	3.21e-05	0.000333	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KCNMA1—kidney cancer	3.16e-05	0.000328	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ST3GAL2—kidney cancer	3.15e-05	0.000327	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.14e-05	0.000326	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.13e-05	0.000325	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GSTM1—kidney cancer	3.12e-05	0.000324	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ALDH1A1—kidney cancer	3.08e-05	0.00032	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF2—kidney cancer	3.06e-05	0.000318	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	3.03e-05	0.000314	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL2—kidney cancer	3.01e-05	0.000313	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	3e-05	0.000311	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTT1—kidney cancer	2.99e-05	0.000311	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	2.96e-05	0.000307	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PGK1—kidney cancer	2.96e-05	0.000307	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC5A3—kidney cancer	2.96e-05	0.000307	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP1A1—kidney cancer	2.96e-05	0.000307	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ACY1—kidney cancer	2.95e-05	0.000306	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—LDHB—kidney cancer	2.9e-05	0.000301	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	2.9e-05	0.0003	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	2.9e-05	0.0003	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	2.9e-05	0.0003	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VEGFA—kidney cancer	2.89e-05	0.0003	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—POMC—kidney cancer	2.85e-05	0.000296	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—POMC—kidney cancer	2.85e-05	0.000296	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RAF1—kidney cancer	2.81e-05	0.000292	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RAF1—kidney cancer	2.81e-05	0.000292	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—PTGS1—kidney cancer	2.81e-05	0.000291	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ERBB2—kidney cancer	2.78e-05	0.000289	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ERBB2—kidney cancer	2.78e-05	0.000289	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—GRB7—kidney cancer	2.76e-05	0.000286	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—kidney cancer	2.76e-05	0.000286	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MTOR—kidney cancer	2.74e-05	0.000285	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MTOR—kidney cancer	2.74e-05	0.000285	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CD4—kidney cancer	2.74e-05	0.000284	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CD4—kidney cancer	2.74e-05	0.000284	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTGS2—kidney cancer	2.72e-05	0.000282	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTGS2—kidney cancer	2.72e-05	0.000282	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ACY1—kidney cancer	2.58e-05	0.000268	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CDKN1B—kidney cancer	2.58e-05	0.000267	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CDKN1B—kidney cancer	2.58e-05	0.000267	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITPR2—kidney cancer	2.57e-05	0.000266	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—VEGFA—kidney cancer	2.56e-05	0.000266	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TP53—kidney cancer	2.55e-05	0.000265	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.54e-05	0.000263	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA9—kidney cancer	2.51e-05	0.000261	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.51e-05	0.000261	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PDHB—kidney cancer	2.51e-05	0.00026	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCB1—kidney cancer	2.48e-05	0.000257	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.46e-05	0.000255	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CTNNB1—kidney cancer	2.43e-05	0.000252	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—CTNNB1—kidney cancer	2.43e-05	0.000252	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PTEN—kidney cancer	2.37e-05	0.000246	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PTEN—kidney cancer	2.37e-05	0.000246	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CCBL1—kidney cancer	2.36e-05	0.000244	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTGS2—kidney cancer	2.28e-05	0.000236	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTGS2—kidney cancer	2.28e-05	0.000236	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—POMC—kidney cancer	2.2e-05	0.000229	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PDHB—kidney cancer	2.2e-05	0.000228	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CRABP1—kidney cancer	2.14e-05	0.000222	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.13e-05	0.000221	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	2.11e-05	0.000219	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.08e-05	0.000215	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CCBL1—kidney cancer	2.06e-05	0.000214	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.05e-05	0.000212	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PPAT—kidney cancer	2.04e-05	0.000212	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GLIPR1—kidney cancer	2.04e-05	0.000212	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK3—kidney cancer	2.03e-05	0.00021	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK3—kidney cancer	2.03e-05	0.00021	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.02e-05	0.000209	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2e-05	0.000207	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ITPR2—kidney cancer	1.99e-05	0.000206	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PTEN—kidney cancer	1.99e-05	0.000206	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PTEN—kidney cancer	1.99e-05	0.000206	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—kidney cancer	1.97e-05	0.000204	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—kidney cancer	1.97e-05	0.000204	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MAPK1—kidney cancer	1.93e-05	0.0002	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MAPK1—kidney cancer	1.93e-05	0.0002	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—GSTM1—kidney cancer	1.91e-05	0.000198	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—APRT—kidney cancer	1.9e-05	0.000197	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FH—kidney cancer	1.9e-05	0.000197	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA1—kidney cancer	1.88e-05	0.000195	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	1.88e-05	0.000195	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.86e-05	0.000193	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.83e-05	0.00019	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KRAS—kidney cancer	1.82e-05	0.000189	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KRAS—kidney cancer	1.82e-05	0.000189	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ACHE—kidney cancer	1.81e-05	0.000188	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTT1—kidney cancer	1.81e-05	0.000188	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	1.81e-05	0.000188	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GLIPR1—kidney cancer	1.79e-05	0.000186	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PPAT—kidney cancer	1.79e-05	0.000186	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPC3—kidney cancer	1.79e-05	0.000185	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.78e-05	0.000185	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTGS2—kidney cancer	1.76e-05	0.000182	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IFNA2—kidney cancer	1.75e-05	0.000182	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.74e-05	0.000181	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA2—kidney cancer	1.74e-05	0.00018	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SCARB1—kidney cancer	1.72e-05	0.000178	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS1—kidney cancer	1.7e-05	0.000176	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALAD—kidney cancer	1.69e-05	0.000176	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAF1—kidney cancer	1.69e-05	0.000175	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.68e-05	0.000175	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PIK3CA—kidney cancer	1.67e-05	0.000174	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PIK3CA—kidney cancer	1.67e-05	0.000174	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSMD7—kidney cancer	1.67e-05	0.000173	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—APRT—kidney cancer	1.66e-05	0.000173	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FH—kidney cancer	1.66e-05	0.000173	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.66e-05	0.000172	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ST3GAL2—kidney cancer	1.65e-05	0.000171	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.64e-05	0.00017	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ALDH1A1—kidney cancer	1.61e-05	0.000168	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.61e-05	0.000167	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACY1—kidney cancer	1.59e-05	0.000165	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—BCHE—kidney cancer	1.58e-05	0.000164	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF2—kidney cancer	1.58e-05	0.000164	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPC3—kidney cancer	1.56e-05	0.000162	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC5A5—kidney cancer	1.56e-05	0.000162	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PGK1—kidney cancer	1.55e-05	0.000161	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A3—kidney cancer	1.55e-05	0.000161	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PTEN—kidney cancer	1.53e-05	0.000159	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.53e-05	0.000158	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA2—kidney cancer	1.52e-05	0.000158	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.52e-05	0.000158	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—LDHB—kidney cancer	1.52e-05	0.000158	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IL2—kidney cancer	1.51e-05	0.000157	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SLC2A1—kidney cancer	1.51e-05	0.000156	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALAD—kidney cancer	1.48e-05	0.000154	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.47e-05	0.000153	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.46e-05	0.000152	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.45e-05	0.00015	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.45e-05	0.00015	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.45e-05	0.00015	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.44e-05	0.000149	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.41e-05	0.000147	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RAF1—kidney cancer	1.4e-05	0.000145	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PIK3CA—kidney cancer	1.4e-05	0.000145	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PIK3CA—kidney cancer	1.4e-05	0.000145	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.4e-05	0.000145	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A3—kidney cancer	1.36e-05	0.000141	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PGK1—kidney cancer	1.36e-05	0.000141	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PDHB—kidney cancer	1.35e-05	0.00014	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—POMC—kidney cancer	1.35e-05	0.00014	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—LDHB—kidney cancer	1.33e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.33e-05	0.000138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA9—kidney cancer	1.32e-05	0.000137	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.29e-05	0.000133	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VEGFA—kidney cancer	1.28e-05	0.000133	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.27e-05	0.000132	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CCBL1—kidney cancer	1.27e-05	0.000132	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.26e-05	0.000131	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTP1—kidney cancer	1.26e-05	0.00013	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK3—kidney cancer	1.21e-05	0.000126	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.2e-05	0.000124	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ABCB1—kidney cancer	1.19e-05	0.000123	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.16e-05	0.000121	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—MAPK1—kidney cancer	1.16e-05	0.00012	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GSTM1—kidney cancer	1.15e-05	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA9—kidney cancer	1.15e-05	0.00012	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.14e-05	0.000118	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CRABP1—kidney cancer	1.12e-05	0.000116	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PPAT—kidney cancer	1.1e-05	0.000114	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.1e-05	0.000114	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP1A1—kidney cancer	1.09e-05	0.000114	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PIK3CA—kidney cancer	1.08e-05	0.000112	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.07e-05	0.000112	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ITPR2—kidney cancer	1.04e-05	0.000108	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—APRT—kidney cancer	1.03e-05	0.000106	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FH—kidney cancer	1.03e-05	0.000106	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PIK3CA—kidney cancer	1e-05	0.000104	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	9.88e-06	0.000102	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CRABP1—kidney cancer	9.81e-06	0.000102	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPC3—kidney cancer	9.64e-06	0.0001	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—kidney cancer	9.59e-06	9.95e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	9.55e-06	9.91e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTT1—kidney cancer	9.49e-06	9.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ACHE—kidney cancer	9.49e-06	9.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA2—kidney cancer	9.37e-06	9.73e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALAD—kidney cancer	9.14e-06	9.48e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ITPR2—kidney cancer	9.12e-06	9.46e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	8.99e-06	9.33e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SCARB1—kidney cancer	8.98e-06	9.32e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ST3GAL2—kidney cancer	8.92e-06	9.25e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS1—kidney cancer	8.89e-06	9.22e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMD7—kidney cancer	8.72e-06	9.05e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ALDH1A1—kidney cancer	8.72e-06	9.04e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAF1—kidney cancer	8.69e-06	9.01e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PGK1—kidney cancer	8.36e-06	8.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A3—kidney cancer	8.36e-06	8.67e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTT1—kidney cancer	8.31e-06	8.63e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ACHE—kidney cancer	8.31e-06	8.63e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—BCHE—kidney cancer	8.26e-06	8.58e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—LDHB—kidney cancer	8.19e-06	8.5e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC5A5—kidney cancer	8.16e-06	8.47e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—kidney cancer	8.16e-06	8.47e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SLC2A1—kidney cancer	7.88e-06	8.18e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SCARB1—kidney cancer	7.87e-06	8.17e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS1—kidney cancer	7.79e-06	8.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IL2—kidney cancer	7.79e-06	8.08e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.65e-06	7.94e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMD7—kidney cancer	7.64e-06	7.93e-05	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RAF1—kidney cancer	7.52e-06	7.8e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—BCHE—kidney cancer	7.24e-06	7.51e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC5A5—kidney cancer	7.15e-06	7.42e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA9—kidney cancer	7.1e-06	7.37e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SLC2A1—kidney cancer	6.91e-06	7.17e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.67e-06	6.92e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VEGFA—kidney cancer	6.62e-06	6.87e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.59e-06	6.84e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTP1—kidney cancer	6.58e-06	6.82e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTGS2—kidney cancer	6.51e-06	6.75e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK3—kidney cancer	6.26e-06	6.5e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ABCB1—kidney cancer	6.22e-06	6.46e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GSTM1—kidney cancer	6.04e-06	6.27e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CRABP1—kidney cancer	6.04e-06	6.27e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MAPK1—kidney cancer	5.96e-06	6.18e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTP1—kidney cancer	5.76e-06	5.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP1A1—kidney cancer	5.73e-06	5.94e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PTEN—kidney cancer	5.67e-06	5.89e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—KRAS—kidney cancer	5.63e-06	5.84e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ITPR2—kidney cancer	5.62e-06	5.83e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GSTM1—kidney cancer	5.29e-06	5.49e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PIK3CA—kidney cancer	5.17e-06	5.36e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACHE—kidney cancer	5.12e-06	5.31e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTT1—kidney cancer	5.12e-06	5.31e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP1A1—kidney cancer	5.02e-06	5.21e-05	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TP53—kidney cancer	5e-06	5.19e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SCARB1—kidney cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS1—kidney cancer	4.8e-06	4.98e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.71e-06	4.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMD7—kidney cancer	4.71e-06	4.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—BCHE—kidney cancer	4.46e-06	4.63e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.41e-06	4.57e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—kidney cancer	4.27e-06	4.43e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.26e-06	4.42e-05	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PIK3CA—kidney cancer	4e-06	4.15e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—kidney cancer	3.74e-06	3.88e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTP1—kidney cancer	3.55e-06	3.68e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTGS2—kidney cancer	3.41e-06	3.54e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ABCB1—kidney cancer	3.36e-06	3.49e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GSTM1—kidney cancer	3.26e-06	3.39e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.09e-06	3.21e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTGS2—kidney cancer	2.99e-06	3.1e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PTEN—kidney cancer	2.97e-06	3.08e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PTEN—kidney cancer	2.6e-06	2.7e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—kidney cancer	2.31e-06	2.39e-05	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PIK3CA—kidney cancer	2.1e-06	2.17e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTGS2—kidney cancer	1.84e-06	1.91e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PIK3CA—kidney cancer	1.84e-06	1.91e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PTEN—kidney cancer	1.6e-06	1.66e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.13e-06	1.17e-05	CbGpPWpGaD
